Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Breast Cancer|Estrogen-receptor Positive Breast Cancer|Cancer, Breast|Breast Cancer Female|Breast Adenocarcinoma|Estrogen Receptor Positive Tumor|ER Positive
Interventions: DRUG: H3B-6545
Sponsor: Eisai Inc.